The Experience of the Derivo® Embolisation Device in Intracranial Aneurysms

Özet

AIM: To investigate the safety and efficacy of Derivo® embolisation device (DED), a new-generation flow diverter designed to treatcerebrovascular aneurysms, and its long-term clinical outcomes.MATERIAL and METHODS: In total, 146 patients with 182 aneurysms were treated with DED. The mean age of the participantswas 51.5 years; among them, 46 (31.5%) presented with acute subarachnoid haemorrhage. The mean aneurysm size was 8.3 mm,and 12 aneurysms were involved the vertebrobasilar system. Ophthalmic aneurysms account for most internal carotid artery (ICA)aneurysms.RESULTS: The Glasgow Coma Scale (GCS) score of 12 patients was <15. DED was associated with a mortality rate of 2.7% andpermanent morbidity rate of 3.4%, and a complete aneurysm occlusion rate was achieved in 78.7% of cases after 7.02 months.CONCLUSION: The DED device is a new-generation flow diverter with excellent opening behaviour and navigational benefits. Ourresults indicated a safe aneurysm occlusion with optimum morbidity and mortality values despite the fact that almost one-third ofthe patients presented with subarachnoid haemorrhage.KEYWORDS: Derivo® embolisation device, Cerebrovasc